Free Trial

Anika Therapeutics Q2 2024 Earnings Report

Anika Therapeutics logo
$16.62 -0.32 (-1.89%)
(As of 12/17/2024 ET)

Anika Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
$0.23
Beat/Miss
Missed by -$0.24
One Year Ago EPS
-$0.06

Anika Therapeutics Revenue Results

Actual Revenue
$41.92 million
Expected Revenue
$39.90 million
Beat/Miss
Beat by +$2.02 million
YoY Revenue Growth
N/A

Anika Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

A conspiracy Trump won’t unseal (Ad)

New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.

This is the untold, true story of God’s Investment.

Anika Therapeutics Earnings Headlines

Anika To Participate in December 2024 Investor Conferences
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
A conspiracy Trump won’t unseal
New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.
Anika Therapeutics price target lowered to $25 from $37 at Barrington
Anika (ANIK) Earnings Dates & Reports
See More Anika Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anika Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anika Therapeutics and other key companies, straight to your email.

About Anika Therapeutics

Anika Therapeutics (NASDAQ:ANIK), a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

View Anika Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings